Rigel Pharmaceuticals was kicked in the stomach earlier this month, when AstraZeneca returned full rights for fostamatinib. The Big Pharma member decided to write off $140 million of assets attributed to the partnership rather than take the next steps in commercializing the drug for rheumatoid arthritis. Ouch. While it's a smart idea for AstraZeneca to walk away now, Rigel is in a tough spot with its top drug candidate receiving a vote of no confidence. There is a handful of companies that stand to benefit from fostamatinib's failure. In the following video, Fool contributor Maxx Chatsko explains what it means for investors and what the future could hold for the development-stage company.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article 3 Winners and 2 Losers From Rigel's Failure originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio or his CAPS page, or follow him on Twitter, @BlacknGoldFool, to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.